Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2015-07-15 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2015-07-15 English
FORM 4 SUBMISSION
Director's Dealing
2015-07-15 English
FORM 4 SUBMISSION
Director's Dealing
2015-07-15 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 1, 2015, reporting on the results of the Annual Meeting of Stockholders held on June 25, 2015. It details the voting results on director elections, appointment of auditors, and stock option plan ratification. The content focuses exclusively on the submission of matters to a vote of security holders and the official voting outcomes. There is no financial data, management discussion, or other report content. The document is a formal announcement of voting results from the Annual General Meeting, matching the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3720 characters, which is consistent with a voting results announcement rather than a full report or proxy statement. Therefore, the correct classification is DVA with high confidence.
2015-07-01 English
FORM 4 SUBMISSION
Director's Dealing
2015-06-12 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the number of shares registered, the stock option plan, and signatures of company officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under Regulatory Filings (RNS). The document length is 8945 characters, which is substantial and contains the full registration statement, not just an announcement.
2015-06-12 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.